| Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. | |
| | |
MedLine Citation:
|
PMID: 19811543 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The efficacy of highly purified VWF/FVIII concentrates with standardized ristocetin cofactor content (VWF:RCo) has been already proven in patients with von Willebrand's disease (VWD). Aim of this retrospective study is to confirm efficacy and safety of two highly purified, doubly virus-inactivated VWF/FVIII concentrates in a large cohort of patients with VWD who were characterized at enrolment by bleeding severity score. Study drugs Alphanate or Fanhdi were given to 120 cases (51 males, 69 females, median age 50 years, range 6-83 years). Patients had VWD3 (10), VWD2A (19), VWD2B (25), VWD2M (10) and DDAVP-unresponsive VWD1 (56) and a median bleeding severity score of 8 (range 0-27). A total of 114 bleeding episodes in 55 cases and 131 surgical procedures in 85 cases could be analysed. Excellent-good clinical responses were seen in 97% of bleeding episodes and in 99% of surgical procedures. To prevent recurrent gastrointestinal (GI) bleeding, cerebral (CNS) haemorrhage, haemarthroses, urogenital or multisite bleeding in more severe patients, secondary prophylaxis was also carried out in 15 cases with VWD3 (3), VWD2A (3), VWD2B (2), VWD1 (7). A median dose of 42 IU VWF:RCo kg(-1) given every other day or twice a week over a median period of 334 days (range 24-799) prevented bleeding completely in 13 cases and reduced its incidence in the remaining two. These results confirm the efficacy and safety of the study concentrates, not only in the management of bleeding and surgery but also in secondary prophylaxis of severe VWD. |
| | |
Authors:
|
A B Federici; G Barillari; E Zanon; M G Mazzucconi; R Musso; R Targhetta; P M Mannucci |
Related Documents
:
|
18848103 - Exodontia and antiplatelet therapy. 1526413 - Factors associated with failure of propranolol for the prevention of first bleeding in ... 1323593 - Rifabutin and ethambutol do not help recurrent crohn's disease in the neoterminal ileum. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-10-06 |
Journal Detail:
|
Title: Haemophilia : the official journal of the World Federation of Hemophilia Volume: 16 ISSN: 1365-2516 ISO Abbreviation: Haemophilia Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2010-07-29 Completed Date: 2011-01-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9442916 Medline TA: Haemophilia Country: England |
Other Details:
|
Languages: eng Pagination: 101-10 Citation Subset: IM |
Affiliation:
|
Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Department of Medicine and Medical Specialties, IRCCS Foundation Ospedale Maggiore, Mangiagalli, Regina Elena and Universita degli Studi di Milano, Via Pace 9, Milan, Italy. augusto.federici@unimi.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Blood Loss, Surgical / prevention & control Child Cohort Studies Drug Combinations Factor VIII / therapeutic use* Female Hemorrhage / epidemiology, prevention & control Humans Male Middle Aged Retrospective Studies Severity of Illness Index Virus Inactivation Young Adult von Willebrand Diseases / drug therapy* von Willebrand Factor / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations; 0/von Willebrand Factor; 9001-27-8/Factor VIII |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 2-Methylhopanoids are maximally produced in akinetes of Nostoc punctiforme: geobiological implicatio...
Next Document: Patient factors in the implementation of decision aids in general practice: a qualitative study.